Urimax%25252525252525252525252525252525252525252525252525252525252525252525252520%25252525252525252525252525252525252525252525252525252525252525252525252528tamsulosin%25252525252525252525252525252525252525252525252525252525252525252525252529

# Urimax (Tamsulosin) ## Overview Tamsulosin is a selective alpha-1 adrenergic receptor antagonist that preferentially blocks alpha-1A receptors in the prostate, leading to smooth muscle relaxation in the prostate and bladder neck, thereby improving urinary flow. ## Primary Indications * Signs and symptoms of Benign Prostatic Hyperplasia (BPH). * Off-label: Medical Expulsive Therapy (MET) for ureteral calculi. ## Adult Dosing * **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day. * **Maximum Dose:** If no response after 2-4 weeks, the dose may be increased to 0.8 mg daily. ## Pediatric Dosing * **Not indicated/Not established.** Safety and efficacy have not been established in the pediatric population. ## Dose Adjustments * **Renal Impairment:** No specific adjustment required; use with caution in patients with severe renal impairment (CrCl < 10 mL/min). * **Hepatic Impairment:** Avoid in patients with severe hepatic impairment (Child-Pugh class C). * **CYP3A4/2D6 Inhibitors:** Reduce dose or avoid concurrent administration with potent inhibitors. ## Contraindications * Hypersensitivity to tamsulosin or any component of the formulation. * Concurrent use of potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin). ## Adverse Effects * **Common:** Dizziness, headache, abnormal ejaculation (retrograde), rhinitis, asthenia. * **Serious:** Orthostatic hypotension (rare but significant), syncope, severe allergic reactions, Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery. ## Key Drug Interactions * **CYP3A4/2D6 Inhibitors:** Significant increase in tamsulosin plasma concentrations. * **PDE-5 Inhibitors (e.g., sildenafil, tadalafil):** Increased risk of symptomatic hypotension; initiate at the lowest dose. * **Antihypertensives:** Potential for additive hypotensive effects. ## Monitoring * Monitor for orthostatic hypotension, particularly upon initiation or dose escalation. * Monitor urinary symptom scores (e.g., AUA-SI or IPSS) to assess therapeutic response. * Screen for history of cataract/glaucoma before surgery; inform ophthalmologist of current or past tamsulosin use. ## Clinical Pearls * **Take with food:** Always administer 30 minutes after the same meal daily to maintain consistent systemic exposure. * **First dose effect:** Although less common than with non-selective alpha-blockers, warn patients of potential dizziness upon standing. * **IFIS:** Tamsulosin is strongly associated with Intraoperative Floppy Iris Syndrome. Advise patients to inform their surgeon if they are planning cataract or glaucoma surgery. * **Not a Prostate-Shrinker:** Unlike 5-alpha-reductase inhibitors (e.g., finasteride), tamsulosin does not reduce prostate size or alter PSA levels significantly. *** *Disclaimer: This information is for educational purposes only. Drug information is subject to change based on evolving evidence and local institutional protocols. Always verify current prescribing information, package inserts, and clinical guidelines before prescribing or dispensing any medication.*